[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

LV10048A - Lidzeklis slimibu arstesanai un ta iegusanas process - Google Patents

Lidzeklis slimibu arstesanai un ta iegusanas process

Info

Publication number
LV10048A
LV10048A LV920173A LV920173A LV10048A LV 10048 A LV10048 A LV 10048A LV 920173 A LV920173 A LV 920173A LV 920173 A LV920173 A LV 920173A LV 10048 A LV10048 A LV 10048A
Authority
LV
Latvia
Prior art keywords
getting
tool
treating illness
illness
treating
Prior art date
Application number
LV920173A
Other languages
English (en)
Other versions
LV10048B (en
Inventor
Michael Dr Lobisch
Ralph Dr Venhaus
Bernd Dr Nickel
Istvan Prof Szelenyi
Juergen Prof Engel
Peter Dr Emig
Original Assignee
Asta Medica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Medica Ag filed Critical Asta Medica Ag
Publication of LV10048A publication Critical patent/LV10048A/lv
Publication of LV10048B publication Critical patent/LV10048B/lv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Golf Clubs (AREA)
  • Details Of Television Scanning (AREA)
  • Paints Or Removers (AREA)
  • Medicines Containing Plant Substances (AREA)
LVP-92-173A 1990-07-14 1992-10-27 Medical agent and method for producing thereof LV10048B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4022442 1990-07-14
IN421CA1991 IN172468B (lv) 1990-07-14 1991-06-04

Publications (2)

Publication Number Publication Date
LV10048A true LV10048A (lv) 1994-05-10
LV10048B LV10048B (en) 1995-06-20

Family

ID=25895002

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-92-173A LV10048B (en) 1990-07-14 1992-10-27 Medical agent and method for producing thereof

Country Status (30)

Country Link
US (2) US5162346A (lv)
EP (2) EP0659410B1 (lv)
KR (1) KR0182811B1 (lv)
CN (1) CN1070700C (lv)
AT (2) ATE133564T1 (lv)
AU (1) AU634073B2 (lv)
CA (1) CA2046943C (lv)
CZ (1) CZ280879B6 (lv)
DE (3) DE4122166A1 (lv)
DK (2) DK0467164T3 (lv)
EG (1) EG19814A (lv)
ES (2) ES2082887T3 (lv)
GR (1) GR3019179T3 (lv)
HR (1) HRP920667B1 (lv)
HU (1) HU206973B (lv)
IE (1) IE74688B1 (lv)
IL (1) IL98810A (lv)
IN (1) IN172468B (lv)
LT (1) LT3593B (lv)
LV (1) LV10048B (lv)
MC (1) MC2272A1 (lv)
MX (1) MX9100160A (lv)
NO (1) NO912758L (lv)
NZ (1) NZ238940A (lv)
PT (1) PT98291B (lv)
RO (1) RO108220B1 (lv)
RU (1) RU2070408C1 (lv)
SI (1) SI9111227B (lv)
SK (1) SK279567B6 (lv)
ZA (1) ZA915466B (lv)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0560092T3 (da) * 1992-03-11 1998-08-10 Asta Medica Ag Tabletter, granulater og pellets med højt indholdaf aktivstoffer til højkoncentrerede, faste administreringsformer
DE4319649A1 (de) * 1993-03-18 1994-09-22 Asta Medica Ag Feste Flupirtin enthaltende orale Darreichungsformen mit kontrollierter Wirkstoffabgabe
DE4327516A1 (de) * 1993-08-17 1995-02-23 Asta Medica Ag Primäre und sekundäre neuroprotektive Wirkung bei neurodegenerativen Erkrankungen von Flupirtin
GB9426079D0 (en) * 1994-12-23 1995-02-22 Orion Yhtymae Oy A gelatine capsule
DE19541405A1 (de) * 1995-11-07 1997-05-15 Asta Medica Ag Verwendung von Flupirtin zur Prophylaxe und Therapie von Erkrankungen, die mit einer Beeinträchtigung des hämatopoetischen Zellsystems einhergehen
US6284794B1 (en) 1996-11-05 2001-09-04 Head Explorer Aps Method for treating tension-type headache with inhibitors of nitric oxide and nitric oxide synthase
US6610324B2 (en) * 1999-04-07 2003-08-26 The Mclean Hospital Corporation Flupirtine in the treatment of fibromyalgia and related conditions
RU2002105502A (ru) * 1999-08-03 2004-03-20 АВД.фарма ГмбХ унд Ко. КГ (DE) Применение флупиртина для облегчения болей, вызванных дегенеративными заболеваниями суставов у собак и кошек
US6821995B1 (en) 1999-12-01 2004-11-23 Duke University Method of treating batten disease
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
RU2213565C1 (ru) * 2002-06-24 2003-10-10 Общество с ограниченной ответственностью "Паркинфарм" Способ лечебного воздействия на организм пациента при лечении болезни паркинсона
DE10255415A1 (de) * 2002-11-28 2004-06-09 Bayer Healthcare Ag Dermale Applikation von Flupirtin
DE10327674A1 (de) * 2003-06-20 2005-01-05 Awd.Pharma Gmbh & Co. Kg Injizierbare Darreichungsform von Flupirtin
US20050089559A1 (en) 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
DE102004001558A1 (de) * 2004-01-10 2005-08-18 Bayer Healthcare Ag Arzneimittel zur topischen Applikation bei Tieren
US20050196461A1 (en) * 2004-01-14 2005-09-08 Udell Ronald G. Ceramide formulations suitable for oral administration
KR20060124731A (ko) * 2004-01-29 2006-12-05 뉴로몰레큘라 파마슈티칼스, 인코포레이티드 중추신경계-관련 질환 치료용 ｎｍｄａ 수용체 길항제 및ｍａｏ-억제제 또는 ｇａｄｐｈ-억제제의 배합물
US20050220862A1 (en) 2004-03-31 2005-10-06 Bernstein Joel E Compositions with reduced hepatotoxicity
US7619007B2 (en) * 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
EP1688141A1 (en) * 2005-01-31 2006-08-09 elbion AG The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome
RU2007140348A (ru) 2005-04-06 2009-05-20 Адамас Фармасьютикалс, Инк. (Us) Способы и композиции для лечения заболеваний цнс
EP2012769A1 (en) * 2006-05-02 2009-01-14 Rundfeldt, Chris Potassium channel activators for the prevention and treatment of dystonia and dystonia-like symptoms
US7960436B2 (en) * 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
DK2061465T3 (da) * 2006-08-23 2013-07-08 Valeant Pharmaceuticals Int Derivater af 4-(N-azacycloalkyl)anilider som kaliumkanalmodulatorer
US8993593B2 (en) * 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
US8722929B2 (en) * 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
EA200900749A1 (ru) * 2006-11-28 2009-12-30 Валеант Фармасьютикалс Интернэшнл 1,4-диаминобициклические аналоги ретигабина как модуляторы калиевых каналов
US20080279930A1 (en) * 2007-05-07 2008-11-13 Bernd Terhaag Controlled-Release Flupirtine Compositions, Compacts, Kits and Methods of Making and Use Thereof
US8367684B2 (en) * 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) * 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
EP2185149A1 (en) * 2007-08-01 2010-05-19 H. Lundbeck A/S Use of kncq potassium channel openers for reducing symptoms of or treating disorders or conditions wherein the dopaminergic system is disrupted
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
ES2347119B2 (es) * 2009-04-22 2011-04-28 Universidad De Santiago De Compostela Nanocapsulas de poliarginina.
DE102010030053A1 (de) 2010-06-14 2011-12-15 Awd.Pharma Gmbh & Co.Kg Injizierbare Darreichungsform von Flupirtin
JP6251667B2 (ja) * 2014-06-03 2017-12-20 アサヒカルピスウェルネス株式会社 錠剤型即放性製剤及びその製造方法
DE102017007385A1 (de) 2017-08-02 2019-02-07 Christoph Hoock Maleatfreie feste Arzneimittelformen

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1795858C2 (de) 1968-07-19 1979-01-11 Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler, 6000 Frankfurt Benzylaminopyridine
DE3133519A1 (de) 1980-09-13 1982-06-09 Degussa Ag, 6000 Frankfurt "2-amino-3-carbethoxyamino-6-(p-fluor-benzylamino)-pyridin-maleat"
DE3665538D1 (en) * 1985-01-23 1989-10-19 Asta Pharma Ag Synergistic combination of flupirtin and non-steroidal anti-phlogistics
EP0193056B1 (de) * 1985-02-23 1989-06-07 ASTA Pharma Aktiengesellschaft Kombination von Flupirtin und anticholinergisch wirkenden Spasmolytika
DE3604575A1 (de) * 1985-02-23 1986-08-28 Degussa Ag, 6000 Frankfurt Kombination von flupirtin und anticholinergisch wirkenden spasmolytika
FI855016A (fi) * 1985-06-28 1986-12-29 Degussa Synergistisk kombination av flupirtin och 4-acetamido-fenol.

Also Published As

Publication number Publication date
ES2082887T3 (es) 1996-04-01
LV10048B (en) 1995-06-20
EG19814A (en) 1996-02-29
ES2164111T3 (es) 2002-02-16
HU206973B (en) 1993-03-01
AU8040391A (en) 1992-01-16
NO912758L (no) 1992-01-15
IL98810A0 (en) 1992-07-15
DK0659410T3 (da) 2001-12-27
EP0467164B1 (de) 1996-01-31
EP0659410A3 (de) 1995-10-25
IE74688B1 (en) 1997-07-30
KR0182811B1 (ko) 1999-05-01
MC2272A1 (fr) 1993-06-23
US5284861A (en) 1994-02-08
ZA915466B (en) 1992-04-29
NZ238940A (en) 1997-05-26
RO108220B1 (ro) 1994-03-31
PT98291A (pt) 1992-05-29
DK0467164T3 (da) 1996-03-04
GR3019179T3 (en) 1996-06-30
DE4122166A1 (de) 1992-01-16
ATE133564T1 (de) 1996-02-15
CA2046943A1 (en) 1992-01-15
RU2070408C1 (ru) 1996-12-20
MX9100160A (es) 1992-02-28
EP0467164A3 (en) 1992-04-15
CN1058716A (zh) 1992-02-19
HRP920667A2 (en) 1996-10-31
EP0467164A2 (de) 1992-01-22
CA2046943C (en) 1996-03-12
NO912758D0 (no) 1991-07-12
SI9111227A (en) 1995-06-30
IL98810A (en) 1996-01-19
SI9111227B (sl) 2000-12-31
HU912359D0 (en) 1991-12-30
AU634073B2 (en) 1993-02-11
CS210191A3 (en) 1992-02-19
PT98291B (pt) 1999-01-29
LTIP919A (en) 1995-03-27
HRP920667B1 (en) 1998-06-30
EP0659410B1 (de) 2001-10-17
SK279567B6 (sk) 1999-01-11
DE59107331D1 (de) 1996-03-14
EP0659410A2 (de) 1995-06-28
IE912451A1 (en) 1992-01-15
DE59109222D1 (de) 2001-11-22
KR920002147A (ko) 1992-02-28
ATE206919T1 (de) 2001-11-15
IN172468B (lv) 1993-08-14
LT3593B (en) 1995-12-27
HUT59313A (en) 1992-05-28
CZ280879B6 (cs) 1996-04-17
US5162346A (en) 1992-11-10
CN1070700C (zh) 2001-09-12

Similar Documents

Publication Publication Date Title
LV10048A (lv) Lidzeklis slimibu arstesanai un ta iegusanas process
EP0751709A4 (en) METHODS FOR USE OF BCL-2 IN THERAPEUTIC TREATMENT AND PREVENTION OF DISEASES
ATE235906T1 (de) Substituierte phenylpyrimidine derivate, für die behandlung oder prevention von zns-erkrankungen
DE69435243D1 (de) Verwendung vom neurotoxischem Komponent von Botulinum Toxin zur Behandlung von Glattmuskelkrankheiten
EP0363415A4 (en) Compounds for the treatment of alzheimer's disease
DE69222396D1 (de) Verfahren zum Aufbereiten von Kohlenwasserstoffen
GR3035957T3 (en) Use of riluzole for treating aids-related neural disorders
FI942152A0 (fi) Menetelmä työkappaleiden märkäkemialliseen käsittelyyn
PL275056A1 (en) Method of obtaining derivatives of 4-aminopyridine
DE59106539D1 (de) Verfahren zur Oberflächenbehandlung von Bauteilen.
BR8801529A (pt) Processo para o tratamento de lama residual e aparelho para tratamento de lama de tinta
NO944339D0 (no) Melatoninderivater for anvendelse ved behandling av sövnforstyrrelser
NO944340D0 (no) Melatoninderivater for anvendelse ved behandling av desynkroniseringstilstander
DE69525434D1 (de) Verfahren zur keimungshemmenden Behandlung von Knollen oder Zwiebeln
BR9007874A (pt) Processo para o tratamento posterior de tenso-ativos anfoteros ou zwitterionicos
MX9101031A (es) Metodo para tratar trastornos respiratorios
FI925944A0 (fi) Arylalkylestrar av 4,5-dihydroxi-9,10-dihydro-9,10-dioxo-2-antracenkarboxylsyra med terapeutisk effekt
ATA129691A (de) Linienkraftregelbares mehrwalzen-glättwerk zur behandlung bahnförmigen gutes
BR9007738A (pt) Metodo de tratamento de couros
BR9307121A (pt) Ferramenta para o tratamento de superfícies de componentes
DE69404370D1 (de) Gelatinase A zur Behandlung von der Alzheimerschen Krankheit
BR9006209A (pt) Processo de tratamento de pecas de couro
DE69830811D1 (de) Verwendung von Oxazolidinonderivaten zur Behandlung von Psoriasis
SE9004160D0 (sv) Method of treating pain